Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when SLS files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: SLS SELLAS Life Sciences Group, Inc. 8-K

SELLAS Life Sciences reports Q1 2026 financial results and corporate update

Filed May 12, 2026 · Period ending May 12, 2026 · ~1 min read

2 key changes 2 sections

Key Changes

  • medium

    SELLAS disclosed financial results for the quarter ended March 31, 2026, along with a corporate update via press release. Specific financial figures and operational details are contained in the attached exhibit.

  • medium

    The 8-K filing itself contains minimal detail; investors should review the full press release (Exhibit 99.1) for actual quarterly performance metrics and management commentary.

    Exhibit 99.1 view on EDGAR →

Summary

SELLAS Life Sciences Group filed an 8-K on May 12, 2026, announcing its first quarter 2026 financial results and providing a corporate update. The filing is procedural in nature, with the substantive information contained in an attached press release rather than in the body of the 8-K itself. This is a routine quarterly earnings disclosure for the biotech company.

Retail investors should review the full press release to understand SELLAS's Q1 financial performance, cash position, and any updates on its clinical pipeline or business strategy. As a clinical-stage company, key metrics to watch include cash runway, trial enrollment progress, and any regulatory milestones. The next concrete item to monitor would be management's guidance on upcoming clinical data readouts or financing activities that could impact the company's ability to advance its programs.

Section-by-Section Diff

Event · Item 2.02 — Results of Operations and Financial Condition

~200 words

Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.

1 Added
Added Q1 2026 financial results medium

Added in current filing · verify on EDGAR →

On May 12, 2026, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2026 and providing a corporate update.

SELLAS disclosed its financial results for the first quarter ended March 31, 2026, along with a corporate update. The actual financial figures and operational details are contained in the press release (Exhibit 99.1), which is not included in this 8-K body text.

Event · Item 9.01 — Financial Statements and Exhibits

~100 words

SELLAS filed an 8-K attaching a press release dated May 12, 2026; no material business event disclosed in the filing body.

1 Added
Added Press release exhibit medium

Added in current filing · view on EDGAR →

99.1 Press Release dated May 12, 2026

The company attached a press release dated May 12, 2026 as Exhibit 99.1. The 8-K body does not describe the content of the press release, so the nature of the disclosure cannot be determined from this filing alone.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify